AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05712330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient samples
Description: Patient samples for sputum culture
Study NCT05712330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: parent questionnaire
Description: parent questionnaire
Study NCT05198050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole tablets
Description: Letrozole is a third-generation non-steroidal aromatase inhibitor
Study NCT05198050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Tabets
Description: a synthetic prostaglandin medication
Study NCT05198050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tables with a similar appearance to letrozole
Study NCT05425147 — intervention group
Intervention type: OTHER
Intervention: Perioperative autonomic function assessment
Description: Patients will have BRS and HRV measurements taken for approximately 20 minutes, one day before surgery and on the day of surgery. We use LiDCO rapid to conduct non-invasive pulse and beat-to-beat blood pressure monitoring.
Study NCT05655832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivalink wearable device
Description: a CE marked device modified to add a temperature measurement algorithm in addition to ECG and respiratory rate measurements
Study NCT05400382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Meditation training to help reduce stress and reactivity to pain and other stressors.
Study NCT06162923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-site video group
Description: Each participant will receive standard oral hygiene reinforcement verbally, followed by watching a pre-recorded oral hygiene instruction video on a tablet
Study NCT06162923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote video group
Description: After receiving normal oral hygiene reinforcement verbally, each participant will be sent a video link Whatapps instant message, which they are required to watch at home
Study NCT05277753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-specific T cells CAR-T/CTL and DCvac
Description: Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL
Study NCT05064319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive gabapentin 2-3 times a day for a total of 17 days.
Study NCT05064319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.
Study NCT05252130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NoaScope
Description: Smart digital stethoscope
Study NCT04988061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counselling
Description: Educating and Counselling with personal communication for 10-15 minutes and written information about the importance of early identification and intervention for hearing loss are provided by a physician. Also, the information about hearing screening results and an appointment date are provided by a physician.
Study NCT05885139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exopulse Mollii Suit
Description: Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
Study NCT05885139 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Exopulse Mollii Suit
Description: In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
Study NCT03974256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in the use of the automaton
Description: 2 days training on automaton use
Study NCT05133609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine (AZD1222)
Description: ChAdOx1 nCoV-19 vaccine (AZD1222) in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-third dose).
Study NCT05701371 — intervention group
Intervention type: OTHER
Intervention: Biological samples collection
Description: blood drawing + feces collection in a dedicated device
Study NCT05597345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma
Study NCT04842045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin and Midazolam
Description: The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.~The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight.
Study NCT05127577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: Abdominal massage will be applied to patients at least 30 minutes after morning and evening meals (8:30 in the morning, 20:30 in the evening) for 15 minutes each, similar to the literature \[33,34,38\]. Data of the patients will be collected again 15 minutes after the application of abdominal massage (09:00-09:15 in the morning, 21:00-21:15 in the evening). Abdominal massage will start in the evening of the day the patient is transferred to the clinic (20:30), and will be terminated when the patient defecates. In order to stimulate bowel movements, four basic movements will be used in the abdominal massage to be applied clockwise: superficial effusion, deep effusion, petrissage, and vibration.
Study NCT05389943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of vitamin D3
Description: the effect of oral supplement in postmenopausal women.
Study NCT05389943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 50000 UNT Oral Capsule
Description: In postmenopausal women with BMD less than 32 ng/ml
Study NCT05389943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: milk, Dietary and life style modifications.
Description: Postmenopausal women with BMD greater than 32 ng/ml
Study NCT05389943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk, Dietary and life style modifications.
Description: Postmenopausal women with BMD greater than 32 ng/ml
Study NCT05065645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin Converting Enzyme 2
Description: SAD: single dose; MAD: dosage 2x daily for 7 days
Study NCT05065645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: SAD: single dose; MAD: dosage 2x daily for 7 days
Study NCT04963192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected actimeter to measure physical activity in OSA patients
Description: Connected actimeter worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for OSA patients
Study NCT04963192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected BORA Band to measure physical activity in COPD patients only
Description: Connected BORA Band worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for COPD patients only
Study NCT04963192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPAQ to evaluated physical activity
Description: Physical activity evaluated by IPAQ (International Physical Activity Questionnaire) at the inclusion, M3 and M6
Study NCT04963192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected scale to measure weight
Description: Weight measured by a connected scale, before CPAP or NIV treatment, at M3 and M6
Study NCT04963192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected tensiometer to measure arterial pressure
Description: Arterial pressure measured by a connected tensiometer, before CPAP or NIV treatment, at M3 and M6
Study NCT04963192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected BORA Band to measure oxygen saturation in COPD patients only
Description: Daily oxygen saturation measured by the connected BORA Band for COPD patients only during 6 months
Study NCT04963192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected BORA Band to measure heart rate in COPD patients only
Description: Daily heart rate measured by the connected BORA Band for COPD patients only during 6 months
Study NCT04963192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected BORA Band to measure respiratory rate in COPD patients only
Description: Daily respiratory rate measured by the connected BORA Band for COPD patients only during 6 months
Study NCT04963192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXASCORE to evaluated COPD severity
Description: COPD severity evaluated by the EXASCORE questionnaire at inclusion, M3 and M6 for COPD patients only
Study NCT04963192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epworth scale to evaluate sleepiness
Description: Sleepiness evaluated by the Epworth scale at baseline, M3 and M6
Study NCT04963192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pichot scale to evaluate fatigue
Description: Fatigue evaluated by the Pichot scale at inclusion, M3 and M6
Study NCT04963192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usability questionnaire
Description: Subjective assessment of each device by means of usability questionnaire at M6
Study NCT04963192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF36 questionnaire
Description: Quality of life evaluated by the SF36 questionnaire at inclusion and M6
Study NCT05621265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Text messaging
Description: daily text message
Study NCT06304701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive and writing tests
Description: * Wechsler Adult Intelligence Scale - fourth edition (Similarities and Vocabulary subtests)~* MASC (Movie for assessment of social cognition)~* Rey figure~* BHK (Quick Writing Assessment Scale)~* Descriptive text writing~* Persuasive text writing
Study NCT06304701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognitive and writing tests
Description: * Wechsler Adult Intelligence Scale - fourth edition (Similarities and Vocabulary subtests)~* MASC (Movie for assessment of social cognition)~* Rey figure~* BHK (Quick Writing Assessment Scale)~* Descriptive text writing~* Persuasive text writing
Study NCT00012857 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN
Study NCT05331222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT-1
Description: JT-1 is a physiological salt with recently detected pharmacological properties that warrant testing for its therapeutic potential in chronic rhinitis and chronic sinusitis.
Study NCT06235398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem-cell transplantation
Description: Upfront related donor transplantation
Study NCT05894161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: The designed exercise program will be distributed on everyone. The recommendations will be to train from 30 to 45 minutes, 3 days per week for 6 weeks in addition to walking 30 minutes on the ground surface daily.~1. Diaphragmatic Breathing Exercises: Diaphragmatic breathing (DBRT) or abdominal deep breathing is an expansion of the abdominal area rather than the thoracic area when breathing.~2. Progressive Muscle Relaxation (PMR): The physical element includes the tensing and relaxing of all muscle groups over the face, arms, trunk (abdomen \& chest) and legs.~3. A combination of stretching, stabilization and strengthening exercises of the pelvic-lumbar region:~4. Walking exercise: Walking on the ground surface for 30 minutes every day.
Study NCT05818696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lethal Means Counseling (LMC)
Description: The research interventionist uses a guiding approach to identify methods for secure firearm storage and reflects the participant's reasons for and against secure firearm storage, with a particular focus on the service member's verbalized reasons for wanting to adopt or use the identified storage methods.
Study NCT05818696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Uncertainty - Enhanced (CUE)
Description: CUE consists of a 1-hour manualized intervention that uses interactive content to enhance participant learning of critical intervention components. The session includes (1) psychoeducation regarding the role of IU in exacerbating anxiety/mood sensations, (2) practice identifying and challenging maladaptive thoughts about uncertainty and accompanying distress, and (3) behavioral activities to challenge participants' capacity to handle uncertainty.
Study NCT06056479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external oblique intercostal block
Description: 20 ml of bupivacaine 0.25% will be administered by US into external oblique intercostal plane at the level of sixth rib space .
Study NCT05491083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab & ADG106 (Phase Ib)
Description: Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes
Study NCT05491083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab & ADG106 (Phase II)
Description: Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes
Study NCT06196242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI and CT scan
Description: An MRI scan of the head in about 30 minutes. During the scan, MRI thermometry will be performed to monitor for possible lead heating due to the interaction of the MRI radiofrequency field and the implanted devices.~An CT plain scan of the head in about 10 minutes.
Study NCT05575271 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network
Description: The implant surgery is performed under general anesthesia. The generator is implanted subcutaneously in the left upper chest or left axillary border. The electrode lead wire is attached to the left mid-cervical vagus nerve through a second incision in the left neck area. The lead wire is passed through a subcutaneous tunnel and attached to the pulse generator.
Study NCT05575271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network
Description: The implant surgery is performed under general anesthesia. The generator is implanted subcutaneously in the left upper chest or left axillary border. The electrode lead wire is attached to the left mid-cervical vagus nerve through a second incision in the left neck area. The lead wire is passed through a subcutaneous tunnel and attached to the pulse generator.
Study NCT05773079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Within 4 to 12 weeks after the first line of treatment, the maintenance treatment of Toripalimab was started, and 240 mg of Toripalimab was injected intravenously every 3 weeks (the maintenance treatment time was not more than 1 year, until there was an intolerable toxic reaction, or disease progression, or withdrawal of consent, or the investigator judged that it was necessary to withdraw from the treatment, or the subject had received treprizumab treatment for a cumulative period of 1 year or other reasons specified in the protocol). During the treatment period, tumor imaging evaluation shall be conducted every 3 months to see the research process description for details, and the evaluation shall be conducted according to the evaluation criteria of recist. If the evaluation is progress, the treatment shall be stopped.
Study NCT05020847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard F75
Description: F-75 contains 75 kcal and 0.9 g protein per 100 ml
Study NCT05020847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alternative F75 with CMV
Description: Alternative F75 With CMV contains cereal flour, oil, sugar, powdered milk with complex mineral-vitamin (CMV)
Study NCT05020847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alternative F75 without CMV
Description: Alternative F75 without CMV contains cereal flour, oil, sugar, powdered milk without complex mineral vitamin (CMV).
Study NCT05960526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extract Binahong
Description: Extract Binahong 2.5% as nasal irrigation solution
Study NCT05960526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline nasal irrigation
Description: NaCl 0.9% as nasal irrigation solution
Study NCT04218903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined training performed four times per week (CT4)
Description: CT4 will perform four combined training sessions per week throughout 12 weeks. Each session will be composed 10-15 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 3 exercises) followed by 20-25 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
Study NCT04218903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined training performed two times per week (CT2)
Description: CT2 will perform two combined training sessions per week throughout 12 weeks. Each session will be composed 20-30 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 6 exercises) followed by 40-50 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
Study NCT05121233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: a single dose 75 mg IV diclofenac by infusion prior to the procedure
Study NCT05121233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose iv placebo (saline ) by infusion prior to the procedure
Study NCT04826809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N95 mask
Description: Standard 1870 N95 one time use mask
Study NCT04826809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nordell single E-100 layer mask
Description: Nordell mask design using one layer of E-100 fabric plus cotton fabric overlay
Study NCT04826809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nordell double E-100 layer mask
Description: Nordell mask design using two layers of E-100 fabric
Study NCT05080751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Behaviors
Description: Materials to be weekly available for intervention group, following a schedule of sessions (six in total): videos, audios, booklets, films, books and other presentations. The intervention will be based online, in a asynchronous modality. Members will self-manage activities.
Study NCT04799028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional cow's milk
Description: Fortified cow's milk
Study NCT04799028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk
Description: Milk with synbiotics and fat blend
Study NCT04799028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Habitual diet
Description: Habitual diet
Study NCT05096780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored caffeinated beverage
Description: 16.9 oz (500 cc), carbonated, zero calorie
Study NCT05096780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored caffeinated beverage
Description: 16.9 oz (500 cc), carbonated, zero calorie
Study NCT04688697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prepectoral implant-based reconstruction
Description: In this group, patients receive breast reconstruction with prosthesis placed to anterior pectoralis major, synthetic mesh is used to enclose the prosthesis and place it to anterior pectoralis major.
Study NCT04688697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subpectoral implant-based reconstruction
Description: In this group, patients receive breast reconstruction with placed to posterior pectoralis major, part of the mesh is placed under the pectoralis major during the operation, and the mesh is used to cover the suture of the prosthesis on the inferior plica, or to directly enclose the lower part of the implant.